Skip to main content
Top
Published in: Insights into Imaging 1/2023

Open Access 01-12-2023 | Rectal Cancer | Educational Review

Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control

Authors: Ilaria Prata, Martina Eriksson, Jasenko Krdzalic, Elma Meershoek-Klein Kranenbarg, Annet G. H. Roodvoets, Regina Beets-Tan, Cornelis J. H. van de Velde, Boudewijn van Etten, Geke A. P. Hospers, Bengt Glimelius, Per J. Nilsson, Corrie A. M. Marijnen, Koen C. M. J. Peeters, Lennart K. Blomqvist

Published in: Insights into Imaging | Issue 1/2023

Login to get access

Abstract

Background

Magnetic resonance (MR) imaging is the modality used for baseline assessment of locally advanced rectal cancer (LARC) and restaging after neoadjuvant treatment. The overall audited quality of MR imaging in large multicentre trials on rectal cancer is so far not routinely reported.

Materials and methods

We collected MR images obtained within the Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation (RAPIDO) trial and performed an audit of the technical features of image acquisition. The required MR sequences and slice thickness stated in the RAPIDO protocol were used as a reference.

Results

Out of 920 participants of the RAPIDO study, MR investigations of 668 and 623 patients in the baseline and restaging setting, respectively, were collected. Of these, 304/668 (45.5%) and 328/623 (52.6%) MR images, respectively, fulfilled the technical quality criteria. The main reason for non-compliance was exceeding slice thickness 238/668, 35.6% in the baseline setting and 162/623, 26.0% in the restaging setting. In 166/668, 24.9% and 168/623, 27.0% MR images in the baseline and restaging setting, respectively, one or more of the required pulse sequences were missing.

Conclusion

Altogether, 49.0% of the MR images obtained within the RAPIDO trial fulfilled the image acquisition criteria required in the study protocol. High-quality MR imaging should be expected for the appropriate initial treatment and response evaluation of patients with LARC, and efforts should be made to maximise the quality of imaging in clinical trials and in clinical practice.

Critical relevance statement

This audit highlights the importance of adherence to MR image acquisition criteria for rectal cancer, both in multicentre trials and in daily clinical practice. High-resolution images allow correct staging, treatment stratification and evaluation of response to neoadjuvant treatment.

Key points

- Complying to MR acquisition guidelines in multicentre trials is challenging.
- Neglection on MR acquisition criteria leads to poor staging and treatment.
- MR acquisition guidelines should be followed in trials and clinical practice.
- Researchers should consider mandatory audits prior to study initiation.

Graphical Abstract

Appendix
Available only for authorised users
Literature
2.
go back to reference Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, on behalf of the ESMO Guidelines Working Group* (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Anna Oncol 25:iii1–iii9CrossRef Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, on behalf of the ESMO Guidelines Working Group* (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Anna Oncol 25:iii1–iii9CrossRef
3.
go back to reference van de Velde CJ, Boelens PG, Borras JM et al (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 50(1):1.e-e34 van de Velde CJ, Boelens PG, Borras JM et al (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer 50(1):1.e-e34
4.
go back to reference Beets-Tan RGH, Lambregts DMJ, Maas M et al (2018) Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 28(4):1465–1475PubMedCrossRef Beets-Tan RGH, Lambregts DMJ, Maas M et al (2018) Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 28(4):1465–1475PubMedCrossRef
5.
go back to reference Santiago I, Rodrigues B, Barata M et al (2021) Re-staging and follow-up of rectal cancer patients with MR imaging when “Watch-and-Wait” is an option: a practical guide. Insights Imaging 12(1):114PubMedPubMedCentralCrossRef Santiago I, Rodrigues B, Barata M et al (2021) Re-staging and follow-up of rectal cancer patients with MR imaging when “Watch-and-Wait” is an option: a practical guide. Insights Imaging 12(1):114PubMedPubMedCentralCrossRef
6.
go back to reference Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT (2003) Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90(3):355–364PubMedCrossRef Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT (2003) Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 90(3):355–364PubMedCrossRef
7.
go back to reference Blomqvist L, Glimelius B (2008) The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol 47:5–8 NorwayPubMedCrossRef Blomqvist L, Glimelius B (2008) The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol 47:5–8 NorwayPubMedCrossRef
8.
go back to reference Beets-Tan RG, Lambregts DM, Maas M et al (2013) Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 23(9):2522–2531PubMedCrossRef Beets-Tan RG, Lambregts DM, Maas M et al (2013) Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol 23(9):2522–2531PubMedCrossRef
9.
go back to reference Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42PubMedCrossRef Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22(1):29–42PubMedCrossRef
10.
go back to reference Bahadoer RR (2020) RAPIDO supplementary and protocol Bahadoer RR (2020) RAPIDO supplementary and protocol
11.
12.
go back to reference Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ (2019) MRI of rectal cancer: tumor staging, imaging techniques, and management. Radiographics 39(2):367–87PubMedCrossRef Horvat N, Carlos Tavares Rocha C, Clemente Oliveira B, Petkovska I, Gollub MJ (2019) MRI of rectal cancer: tumor staging, imaging techniques, and management. Radiographics 39(2):367–87PubMedCrossRef
13.
go back to reference Gormly KL, Coscia C, Wells T et al (2016) MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. J Med Imaging Radiat Oncol 60(5):607–615PubMedCrossRef Gormly KL, Coscia C, Wells T et al (2016) MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. J Med Imaging Radiat Oncol 60(5):607–615PubMedCrossRef
14.
15.
go back to reference Srisajjakul S, Prapaisilp P, Bangchokdee S (2018) Pitfalls in MRI of rectal cancer: what radiologists need to know and avoid. Clin Imaging 50:130–140PubMedCrossRef Srisajjakul S, Prapaisilp P, Bangchokdee S (2018) Pitfalls in MRI of rectal cancer: what radiologists need to know and avoid. Clin Imaging 50:130–140PubMedCrossRef
16.
go back to reference Lee JH, Jang HS, Kim JG et al (2014) Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10–01 and 11–02. Radiother Oncol 113(1):18–23PubMedCrossRef Lee JH, Jang HS, Kim JG et al (2014) Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10–01 and 11–02. Radiother Oncol 113(1):18–23PubMedCrossRef
17.
go back to reference Ale Ali H, Kirsch R, Razaz S et al (2019) Extramural venous invasion in rectal cancer: overview of imaging, histopathology, and clinical implications. Abdom Radiol (NY) 44(1):1–10PubMedCrossRef Ale Ali H, Kirsch R, Razaz S et al (2019) Extramural venous invasion in rectal cancer: overview of imaging, histopathology, and clinical implications. Abdom Radiol (NY) 44(1):1–10PubMedCrossRef
18.
go back to reference Kapiteijn E, Marijnen CAM, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638–646PubMedCrossRef Kapiteijn E, Marijnen CAM, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345(9):638–646PubMedCrossRef
19.
go back to reference Lambregts DMJ, Bogveradze N, Blomqvist LK et al (2022) Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 32(7):4991–5003PubMedPubMedCentralCrossRef Lambregts DMJ, Bogveradze N, Blomqvist LK et al (2022) Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur Radiol 32(7):4991–5003PubMedPubMedCentralCrossRef
20.
go back to reference Group TMs (2006) Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333(7572):779CrossRef Group TMs (2006) Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333(7572):779CrossRef
21.
go back to reference Beets-Tan RG, Beets GL (2011) Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging 33(5):1012–1019PubMedCrossRef Beets-Tan RG, Beets GL (2011) Local staging of rectal cancer: a review of imaging. J Magn Reson Imaging 33(5):1012–1019PubMedCrossRef
22.
go back to reference Kirisits C, Federico M, Nkiwane K et al (2015) Quality assurance in MR image guided adaptive brachytherapy for cervical cancer: final results of the EMBRACE study dummy run. Radiother Oncol 117(3):548–554PubMedCrossRef Kirisits C, Federico M, Nkiwane K et al (2015) Quality assurance in MR image guided adaptive brachytherapy for cervical cancer: final results of the EMBRACE study dummy run. Radiother Oncol 117(3):548–554PubMedCrossRef
23.
go back to reference Widder J, Sedlmayer F, Stanek C, Pötter R (2000) Quality assurance in preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-run. Radiother Oncol 56(3):341–347PubMedCrossRef Widder J, Sedlmayer F, Stanek C, Pötter R (2000) Quality assurance in preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-run. Radiother Oncol 56(3):341–347PubMedCrossRef
24.
go back to reference Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28(5):859–865PubMedCrossRef Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 28(5):859–865PubMedCrossRef
25.
go back to reference Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30(14):1620–1627PubMedCrossRef Dewdney A, Cunningham D, Tabernero J et al (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30(14):1620–1627PubMedCrossRef
26.
go back to reference Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR (2012) Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 84(4):949–954PubMedCrossRef Jakobsen A, Ploen J, Vuong T, Appelt A, Lindebjerg J, Rafaelsen SR (2012) Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. Int J Radiat Oncol Biol Phys 84(4):949–954PubMedCrossRef
27.
go back to reference Smith JJ, Chow OS, Gollub MJ et al (2015) Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15:767PubMedPubMedCentralCrossRef Smith JJ, Chow OS, Gollub MJ et al (2015) Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15:767PubMedPubMedCentralCrossRef
28.
go back to reference Achiam MP, Løgager V, Lund Rasmussen V et al (2015) Perioperative Colonic Evaluation in Patients with Rectal Cancer; MR Colonography Versus Standard Care. Acad Radiol 22(12):1522–1528PubMedCrossRef Achiam MP, Løgager V, Lund Rasmussen V et al (2015) Perioperative Colonic Evaluation in Patients with Rectal Cancer; MR Colonography Versus Standard Care. Acad Radiol 22(12):1522–1528PubMedCrossRef
29.
go back to reference Deijen CL, Velthuis S, Tsai A et al (2016) COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc 30(8):3210–3215PubMedCrossRef Deijen CL, Velthuis S, Tsai A et al (2016) COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. Surg Endosc 30(8):3210–3215PubMedCrossRef
30.
go back to reference Glynne-Jones R, Hava N, Goh V et al (2015) Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer 15:764PubMedPubMedCentralCrossRef Glynne-Jones R, Hava N, Goh V et al (2015) Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer 15:764PubMedPubMedCentralCrossRef
31.
go back to reference Burbach JP, Verkooijen HM, Intven M et al (2015) RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials 16:58PubMedPubMedCentralCrossRef Burbach JP, Verkooijen HM, Intven M et al (2015) RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials 16:58PubMedPubMedCentralCrossRef
32.
go back to reference Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF et al (2016) Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 59(4):255–263PubMedCrossRef Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF et al (2016) Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Dis Colon Rectum 59(4):255–263PubMedCrossRef
33.
go back to reference Haddad P, Miraie M, Farhan F et al (2017) Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI-defined T3, T4 or N+ rectal cancer: a randomized clinical trial. Asia Pac J Clin Oncol 13(6):416–422PubMedCrossRef Haddad P, Miraie M, Farhan F et al (2017) Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI-defined T3, T4 or N+ rectal cancer: a randomized clinical trial. Asia Pac J Clin Oncol 13(6):416–422PubMedCrossRef
34.
go back to reference Singh K, Gupta MK, Seam RK, Gupta M (2017) A prospective randomized trial comparing capecitabine-based chemoradiotherapy with 5-FU-based chemoradiotherapy in neoadjuvant setting in locally advanced carcinoma rectum. Indian J Cancer 54(1):347–351PubMedCrossRef Singh K, Gupta MK, Seam RK, Gupta M (2017) A prospective randomized trial comparing capecitabine-based chemoradiotherapy with 5-FU-based chemoradiotherapy in neoadjuvant setting in locally advanced carcinoma rectum. Indian J Cancer 54(1):347–351PubMedCrossRef
35.
go back to reference Lee JL, Lim SB, Yu CS et al (2019) Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial. BMC Cancer 19(1):404PubMedPubMedCentralCrossRef Lee JL, Lim SB, Yu CS et al (2019) Local excision in mid-to-low rectal cancer patients who revealed clinically total or near-total regression after preoperative chemoradiotherapy; a proposed trial. BMC Cancer 19(1):404PubMedPubMedCentralCrossRef
36.
go back to reference Jameson MB, Gormly K, Espinoza D et al (2019) SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. BMC Cancer 19(1):1229PubMedPubMedCentralCrossRef Jameson MB, Gormly K, Espinoza D et al (2019) SPAR - a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. BMC Cancer 19(1):1229PubMedPubMedCentralCrossRef
37.
go back to reference Deng Y, Chi P, Lan P et al (2019) Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol 37(34):3223–3233PubMedPubMedCentralCrossRef Deng Y, Chi P, Lan P et al (2019) Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial. J Clin Oncol 37(34):3223–3233PubMedPubMedCentralCrossRef
38.
go back to reference Nougaret S, Rouanet P, Molinari N et al (2012) MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology 263(2):409–418PubMedCrossRef Nougaret S, Rouanet P, Molinari N et al (2012) MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology 263(2):409–418PubMedCrossRef
39.
go back to reference Conroy T, Bosset J-F, Etienne P-L et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715PubMedCrossRef Conroy T, Bosset J-F, Etienne P-L et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715PubMedCrossRef
40.
go back to reference Akiyoshi T, Shinozaki E, Taguchi S et al (2022) Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). BMJ Open 12(3):e055140PubMedPubMedCentralCrossRef Akiyoshi T, Shinozaki E, Taguchi S et al (2022) Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial). BMJ Open 12(3):e055140PubMedPubMedCentralCrossRef
41.
go back to reference Chen Z, Hu D, Ye G, Xu D (2022) Quantitative evaluation of extramural vascular invasion of rectal cancer by dynamic contrast-enhanced magnetic resonance imaging. Contrast Media Mol Imaging 2022:3038308PubMedPubMedCentral Chen Z, Hu D, Ye G, Xu D (2022) Quantitative evaluation of extramural vascular invasion of rectal cancer by dynamic contrast-enhanced magnetic resonance imaging. Contrast Media Mol Imaging 2022:3038308PubMedPubMedCentral
42.
go back to reference Ominelli J, Araujo ROC, Valadão M et al (2022) Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial. Clin Colorectal Cancer. 21(3):e196–e204PubMedCrossRef Ominelli J, Araujo ROC, Valadão M et al (2022) Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial. Clin Colorectal Cancer. 21(3):e196–e204PubMedCrossRef
Metadata
Title
Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control
Authors
Ilaria Prata
Martina Eriksson
Jasenko Krdzalic
Elma Meershoek-Klein Kranenbarg
Annet G. H. Roodvoets
Regina Beets-Tan
Cornelis J. H. van de Velde
Boudewijn van Etten
Geke A. P. Hospers
Bengt Glimelius
Per J. Nilsson
Corrie A. M. Marijnen
Koen C. M. J. Peeters
Lennart K. Blomqvist
Publication date
01-12-2023
Publisher
Springer Vienna
Published in
Insights into Imaging / Issue 1/2023
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-023-01552-0

Other articles of this Issue 1/2023

Insights into Imaging 1/2023 Go to the issue